HIGHLIGHTS
- who: Anne Perdrix and collaborators from the Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre Bruxelles, Clinical Laboratory, Department of Biopathology, Henri Becquerel Centre, Rouen, France (IRON), Rouen University Hospital, Rouen, France have published the research: PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies, in the Journal: Cancers 2017, 9, 172 of /2017/
- what: Although mutant-p53-dependency appeared to be verified in five studies for breast cancer and four studies for thyroid cancer , the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.